Tourmaline Bio Inc
NASDAQ:TRML
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
5
|
5I5j Holding Group Co Ltd
SZSE:000560
|
CN |
|
H & M Hennes & Mauritz AB
STO:HM B
|
SE |
|
Chewy Inc
NYSE:CHWY
|
US |
|
Sonic Automotive Inc
NYSE:SAH
|
US |
|
Ekopak NV
XBRU:EKOP
|
BE |
|
AVIT Ltd
SZSE:300264
|
CN |
|
People's Insurance Company Group of China Ltd
SSE:601319
|
CN |
Tourmaline Bio Inc
Depreciation & Amortization
Tourmaline Bio Inc
Depreciation & Amortization Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Depreciation & Amortization | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Tourmaline Bio Inc
NASDAQ:TRML
|
Depreciation & Amortization
$40k
|
CAGR 3-Years
-60%
|
CAGR 5-Years
-36%
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Depreciation & Amortization
$8.1B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
5%
|
CAGR 10-Years
26%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Depreciation & Amortization
$2.8B
|
CAGR 3-Years
9%
|
CAGR 5-Years
13%
|
CAGR 10-Years
10%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Depreciation & Amortization
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Depreciation & Amortization
$209.8m
|
CAGR 3-Years
12%
|
CAGR 5-Years
14%
|
CAGR 10-Years
13%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Depreciation & Amortization
$543.7m
|
CAGR 3-Years
17%
|
CAGR 5-Years
18%
|
CAGR 10-Years
22%
|
|
Tourmaline Bio Inc
Glance View
Tourmaline Bio Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Louisville, Kentucky and currently employs 129 full-time employees. The company went IPO on 2021-05-07. Tourmaline Bio, Inc., formerly Talaris Therapeutics, Inc., is a late-stage clinical biotechnology company. The firm is engaged in developing transformative medicines that improve the lives of patients with life-altering immune diseases. The Company’s lead program, TOUR006, is an anti-interleukin-6 (IL-6) antibody that exhibits differentiated properties, including high binding affinity to IL-6 and a naturally long half-life. TOUR006 selectively binds to IL-6, a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory diseases. The firm focuses on developing TOUR006 in thyroid eye disease (TED) and atherosclerotic cardiovascular disease (ASCVD) as its first two indications, with additional indications under consideration. TED is a debilitating autoimmune disorder. ASCVD is a group of disorders caused by plaque buildup and rupture in the artery walls and includes myocardial infarctions (heart attacks) and strokes.
See Also
What is Tourmaline Bio Inc's Depreciation & Amortization?
Depreciation & Amortization
40k
USD
Based on the financial report for Dec 31, 2024, Tourmaline Bio Inc's Depreciation & Amortization amounts to 40k USD.
What is Tourmaline Bio Inc's Depreciation & Amortization growth rate?
Depreciation & Amortization CAGR 5Y
-36%
Over the last year, the Depreciation & Amortization growth was 33%. The average annual Depreciation & Amortization growth rates for Tourmaline Bio Inc have been -60% over the past three years , -36% over the past five years .
